DOXIMITY INC-CLASS A (DOCS)
US26622P1075 - Common Stock
DOCS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. DOCS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DOCS is growing strongly while it is still valued neutral. This is a good combination! With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
In the past year DOCS had a positive cash flow from operations.
Each year in the past 5 years DOCS has been profitable.
Each year in the past 5 years DOCS had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 15.57%, DOCS belongs to the best of the industry, outperforming 97.22% of the companies in the same industry.
DOCS has a Return On Equity of 18.11%. This is amongst the best in the industry. DOCS outperforms 97.22% of its industry peers.
DOCS's Return On Invested Capital of 16.83% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.43%.
The last Return On Invested Capital (16.83%) for DOCS is above the 3 year average (12.02%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.57% | ||
| ROE | 18.11% | ||
| ROIC | 16.83% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
1.3 Margins
DOCS's Profit Margin of 33.69% is amongst the best of the industry. DOCS outperforms 97.22% of its industry peers.
DOCS's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 39.06%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of DOCS has grown nicely.
With an excellent Gross Margin value of 89.94%, DOCS belongs to the best of the industry, outperforming 97.22% of the companies in the same industry.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.06% | ||
| PM (TTM) | 33.69% | ||
| GM | 89.94% |
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DOCS is creating value.
DOCS has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, DOCS has more shares outstanding
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DOCS has an Altman-Z score of 37.24. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DOCS (37.24) is better than 100.00% of its industry peers.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 37.24 |
ROIC/WACC1.86
WACC9.07%
2.3 Liquidity
A Current Ratio of 7.24 indicates that DOCS has no problem at all paying its short term obligations.
The Current ratio of DOCS (7.24) is better than 94.44% of its industry peers.
A Quick Ratio of 7.24 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a better Quick ratio (7.24) than 94.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.24 | ||
| Quick Ratio | 7.24 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.94%, which is quite impressive.
Measured over the past years, DOCS shows a very strong growth in Earnings Per Share. The EPS has been growing by 81.49% on average per year.
DOCS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.27%.
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 40.87% on average per year.
EPS 1Y (TTM)34.94%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)15.27%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%20.44%
3.2 Future
The Earnings Per Share is expected to grow by 12.92% on average over the next years. This is quite good.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.90% yearly.
EPS Next Y13.76%
EPS Next 2Y10.11%
EPS Next 3Y11.1%
EPS Next 5Y12.92%
Revenue Next Year10.85%
Revenue Next 2Y10.16%
Revenue Next 3Y9.5%
Revenue Next 5Y10.9%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
DOCS is valuated quite expensively with a Price/Earnings ratio of 46.62.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
DOCS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.65.
The Price/Forward Earnings ratio is 45.33, which means the current valuation is very expensive for DOCS.
72.22% of the companies in the same industry are more expensive than DOCS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.50. DOCS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.62 | ||
| Fwd PE | 45.33 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DOCS is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than the industry average as 63.89% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.85 | ||
| EV/EBITDA | 36.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)3.39
PEG (5Y)N/A
EPS Next 2Y10.11%
EPS Next 3Y11.1%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DOXIMITY INC-CLASS A
NYSE:DOCS (11/18/2024, 5:06:44 PM)
After market: 52.25 +0.04 (+0.08%)52.21
+2.81 (+5.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.75B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.62 | ||
| Fwd PE | 45.33 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)3.39
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.57% | ||
| ROE | 18.11% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 39.06% | ||
| PM (TTM) | 33.69% | ||
| GM | 89.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.24 | ||
| Quick Ratio | 7.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)34.94%
EPS 3Y81.49%
EPS 5Y
EPS Q2Q%
EPS Next Y13.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.27%
Revenue growth 3Y31.96%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y